A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis
Status:
Completed
Trial end date:
2018-02-21
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug
ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.